[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 7 sources · 21 days · First seen · Last updated

Piramal Pharma business expansion and growth

Overview

Piramal Pharma Limited reported strong financial performance for the first quarter of fiscal year 2027, noting a 17% increase in revenue to ₹2,270 crore and a 72% rise in EBITDA to ₹285 crore. Chairperson Nandini Piramal stated the company had “started FY27 on a strong note,” with growth across its CDMO, complex hospital generics, and consumer-healthcare segments.

Following these financial results, the company expanded its biologics capabilities by acquiring a controlling stake in Yapan Bio Private Limited. By purchasing an additional 40.67% stake for ₹76 crore, Piramal Pharma increased its total equity in the Hyderabad-based CDMO to 74%, transitioning Yapan Bio from an associate to a subsidiary. This acquisition is intended to enhance integrated large molecule services and support the company’s ADCelerate™ platform for antibody-drug conjugate development.

Entities

Piramal Pharma Limited · US Food and Drug Administration · Piramal Pharma Solutions · Peter DeYoung · Nandini Piramal

Timeline

  1. 24 days ago

    [BUSINESS] 7 sources
    Piramal Pharma acquires controlling stake in Yapan Bio

    Piramal Pharma Limited has acquired a controlling 74% stake in Hyderabad-based Yapan Bio for $7.95 million to expand its biologics and vaccine manufacturing capabilities.

  2. about 1 month ago

    [BUSINESS] 4 sources
    Piramal Pharma posts 17% revenue rise and higher EBITDA margin in Q1 FY27

    Piramal Pharma posted 17% revenue growth to ₹2,270 crore and a 12.5% EBITDA margin in Q1 FY27, driven by CDMO expansion and strong performance across its generics and consumer‑health businesses.

Sources

ad-hoc-news.de · businessnewsweek.in · jfoucher.com · medicaldialogues.in · news.cube-soft.jp · onlinemediacafe.com · vir.com.vn